Famitinib Malate

苹果酸法米替尼

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameFamitinib Malate
Drug Alias NameFamitinib maleateMalic acid Famitinib艾比特SHR-1020
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsPlatelet-derived growth factor receptor inhibitorsStem cell growth factor receptor inhibitors +[6] 
TargetsTyrosine-protein kinase receptor FLT3Platelet-derived growth factor receptorStem cell growth factor receptor +[6] 
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Metastatic breast cancerGastroenteropancreatic neuroendocrine tumor +[27] 
Global Approved IndicationsUterine Cervical Neoplasms
Approved Indications in ChinaUterine Cervical Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/27
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHarbin Medical UniversityShanghai Zhongshan HospitalFudan University +[8] 
Inactive CompaniesJiangsu Province Nanjing Brain Hospital
Active IndicationsPancreatic neuroendocrine tumors (pNET)Solid tumoursIdiopathic Pulmonary Fibrosis +[13] 
Inactive IndicationsMetastatic breast cancerGastroenteropancreatic neuroendocrine tumorEndometrial Neoplasms +[14] 

Other Information

ATC CodeN/A
Related LinksN/A